On March 10, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will present at the Oppenheimer 32nd Annual Healthcare Conference being held virtually March 15-17 (Press release, Cue Biopharma, MAR 10, 2022, View Source [SID1234609912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will provide an updated corporate overview and discuss clinical progress from its ongoing clinical trials with CUE-101, its lead and representative drug product candidate from the IL-2 based CUE-100 series in development for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The Company will also discuss anticipated milestones and additional IL-2 based CUE-100 series pipeline progress, including its second IL-2 based candidate CUE-102 with an Investigational New Drug (IND) filing planned for the end of the first quarter 2022.

Presentation Details

Oppenheimer 32nd Annual Healthcare Conference
Date and Time: Thursday, March 17, 2022 at 11:20 a.m. EDT
Webcast link: View Source
A live and archived webcast of the presentation will be available in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.